Article Details

Alpha Biopharma Announces Completion of its EVEREST Phase II/III Clinical Study of ... - EIN News

Retrieved on: 2022-08-25 10:43:00

Tags for this article:

Click the tags to see associated articles and topics

Alpha Biopharma Announces Completion of its EVEREST Phase II/III Clinical Study of ... - EIN News. View article details on hiswai:

Excerpt

Zorifertinib is a next generation EGFR-TKI with full Blood Brain Barrier penetration targeting EGFRm+ NSCLC patients with CNS metastases Top-line ...

Article found on: www.einnews.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up